Ixekizumab (Taltz; Lilly) was found to be superior in improving the signs and symptoms of active psoriatic arthritis (PsA) in biologic disease-modifying anti-rheumatic drug (DMARD)-naive patients compared with adalimumab (Humira; AbbVie), according to results of a Phase 3b/4 study.
The SPIRIT-H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks; patients with moderate-to-severe plaque psoriasis received the approved dose of ixekizumab or adalimumab for that indication. The primary endpoint was simultaneous achievement of at least a 50-percent reduction in disease activity, as defined by the American College of Rheumatology (ACR50), as well as complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI100).
Results showed that ixekizumab was found to be superior to adalimumab in improving PsA, meeting the primary endpoint at week 24. The full results are expected at a scientific meeting sometime in 2019.
Eli Lilly and Company sponsored the study.
For more information visit ClinicalTrials.gov.
This article originally appeared on MPR